The Insurance Regulatory and Development Authority of India (IRDAI) has imposed a six-month ban on Niva Bupa Health Insurance Company, preventing it from establishing any new places of business. This directive, effective August 19, 2026, stems from the insurer's failure to adhere to the prescribed Expense of Management (EoM) limits for the financial year 2024-25.
In addition to the branch ban, the regulator has issued a formal warning to Niva Bupa concerning its EoM compliance. The company confirmed the order in a disclosure to the BSE, stating that it is currently evaluating the decision and intends to take all necessary measures to protect its stakeholders' interests.
Niva Bupa Claims Improved Compliance
Despite the regulatory action for the 2024-25 period, Niva Bupa asserted that its compliance position has since improved. The insurer stated it was compliant with the IRDAI (Expenses of Management, including Commission of Insurers) Regulations, 2024, for the entire financial year ending March 31, 2026. Furthermore, Niva Bupa reported compliance with EoM regulations for the quarter ended June 30, 2026, and anticipates maintaining compliance for the full financial year concluding March 31, 2027.
Understanding Expense of Management (EoM) Limits
Expense of Management limits are crucial regulatory guidelines that dictate the maximum amount insurers can spend on operational costs, including commissions and other administrative expenses, relative to their gross written premium. For health insurance providers, these expenses should not exceed 35% of their gross written premiums within a given financial year.
These regulatory ceilings are designed to ensure that insurers maintain stringent control over their distribution and operating expenditures. The primary objective is to safeguard policyholders by preventing excessive expenses from being passed on through the insurance ecosystem, thereby promoting financial prudence within the industry.
“The regulatory limits are intended to ensure that insurers maintain control over distribution and operating costs while protecting policyholders from excessive expenses being passed through the insurance ecosystem.”
Industry Context and Market Reaction
The IRDAI's action against Niva Bupa unfolds amidst a backdrop of escalating competition within India's insurance sector. Distribution costs and agent commissions have emerged as significant points of concern for the regulator. Rising commission payouts have prompted the IRDAI to scrutinize how insurance distributors are compensated, with a broader aim to mitigate instances of mis-selling and to rein in high distribution costs across the industry.
Following the news of the regulatory action, shares of Niva Bupa closed at Rs 82.61, marking a 1.70% decline from their previous close on the BSE.